Abstract:Abstract Background and Aims Vascular calcifications (VCs) are prevalent in chronic kidney disease (CKD) and mineral disorders, associated with aortic calcification and increased bone fracture risk. The complex pathogenesis involves factors like calcium overload, phosphate imbalance, and secondary hyperparathyroidism. Key inhibitors, vitamin K-dependent proteins (VKDPs) like matrix Gla protein (MGP) and osteocalcin (BGP), play pivotal roles in VC development. Traditional VC risk reduction focuses on lowering parathyroid hormone, calcium and phosphorus levels. Etelcalcetide, a synthetic peptide activating the calcium-sensing receptor, demonstrates promise in clinical trials. Studies on Vitamin K Italian (VIKI) show that calcimimetic treated hemodialysis patients exhibit higher levels of total BGP and MGP, suggesting a protective effect. These findings underscore the multifactorial nature of VC in CKD, informing refined treatment strategies and targeted pathways for improved outcomes. The proposed study will investigate real world evidence of the effect of Etelcalcetide in preserving active forms of VKDPs among total MGP and total BGP with a resulting reduction of those inactive such as dephosphorylated-undercarboxylated MGP or dp-uc MGP, undercarboxylated BGP or uc-BGP, thus contributing to bone and vascular health in hemodialysis patients (Table 1). Method This is a multi-center comparative effectiveness observational longitudinal study with no predefined interference on drug dosing on the part of the investigators. The study will enroll 160 hemodialysis patients: 80 patients considered in the exposed group (treated with Etelcalcetide) and 80 age and sex matched patients considered in the unexposed group (treated with Calcitriol or vitamin D analogs). The treating nephrologist will base their target dose of Etelcalcetide on an individual-level patient basis in order to achieve the KDIGO PTH target level. In the Etelcalcetide-treated group, the addition of calcitriol is allowed when required by normal clinical practice (for correction of hypocalcemia) (Fig. 1). The primary endpoint is the comparison of the levels of active and non-active forms of VKDP between patients treated with Etelcalcetide and those treated with vitamin D or vitamin D analogues. The two groups will be compared for longitudinal changes in the following biomarkers, measured at baseline and after 3, 9, and 18 months of treatment: total MGP, dephosphorylated-undercarboxylated MGP, total BGP, and undercarboxylated BGP. As secondary outcomes will be evaluated bone vascular markers levels, serum calcification propensity T50 test, anemia markers levels, dialysis routine biomarkers, changes from baseline prevalence VCs (Aorta and Iliac arteries) and vertebral fractures by lateral Dorsal Lumbar spine x-Ray and Bone Mass Density (BMD) by Dual-energy X-ray absorptiometry (DEXA). Results Conclusion

Etelcalcetide Use during Maintenance Hemodialysis and Incidence of Parathyroidectomy after Kidney Transplantation

The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients

Parathyroidectomy versus cinacalcet in the treatment of tertiary hyperparathyroidism after kidney transplantation: a retrospective study

Incorporation of Calcimimetics into ESRD Bundle: Changes in Etelcalcetide Utilization and PTH Control Following End of TDAPA Designation

Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study

Use of Etelcalcetide for Preserving Vitamin K-Dependent Protein Activity—An Italian Study

A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation

#2035 Use of ETElcalcetidefor pReserving vitamiN K-dependent proteInactivitYITAlian Study (ETERNITY-ITA Study)

Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism

P1429EVALUATION OF PARATHYROIDECTOMY IN PERSISTENT HYPERARATHYROIDISM AFTER RENAL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY

Timing of parathyroidectomy for tertiary hyperparathyroidism after kidney transplant

Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies

Evaluation of parathyroidectomy for persistent hyperparathyroidism after kidney transplantation: a retrospective study

Treatment with calcimimetics in kidney transplantation

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients

The role of parathyroidectomy in the management of hyperparathyroidism in patients on maintenance haemodialysis and after renal transplantation

Safety and Efficacy of Cinacalcet in Children Aged Under 3 Years on Maintenance Dialysis

New calcimimetics for secondary hyperparathyroidism in CKD G5D: do they offer advantages?

Calcitonin concentrations in patients with chronic kidney disease on hemodialysis in reference to parathyroidectomy